Philips and Concateno Announce Revolutionary Drugs-of-Abuse Testing System
Concateno plc, provider of drug and alcohol testing programmes, and Royal Philips Electronics have announced an innovative handheld drugs-of-abuse detection device. Concateno-Philips pioneering system will make testing for drugs such as cocaine and heroin quicker, simpler and easier enabling immediate point-of-care drug test results, similar to current alcohol tests. Concateno and Philips will deliver the new solution to selected customers in the second half of 2009.
At launch, the Concateno-Philips handheld product will test five drug groups at the same time (cocaine, heroin, methamphetamine, amphetamine and cannabis) in a single saliva sample. Total test time of the new device, from collection of sample to result, will be less than 90 seconds. This represents a significant advance on existing test times, which can take up to five times longer to complete. Other significant features of the test include its sensitivity and ease of use, which has been enhanced by the product's cartridge design and data collection to ensure a reduction in the steps required to obtain results.
Point-of-care testing for drug screening is a test carried out beside or near to the individual being tested, immediately after they have provided a sample for detection. The benefits of point-of-care testing flow from having test results in a few minutes. The need for speed, multi-analytical testing, plus robustness and reliability of method are all central to effective testing.
"This enhanced run time and ease of use will make the new system ideal for worldwide roadside testing, as well as for the criminal justice sector, workplace testing markets and emergency room scenarios where a quick result is key to treatment," said Fiona Begley, Concateno chief executive officer.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Differentiating amino acids: Foundation for direct sequencing of individual proteins developed
Research under high pressure - Why 3,000 bars are needed to take a comprehensive look at a protein
Oxford Gene Technology and Abcodia form Partnership - Companies Combine Expertise to Advance Biomarkers for the Early Diagnosis of Pancreatic Cancer
Targeting a large family of parasites - Potential drug target is identified
Sigma-Aldrich strengthens position in RNAi and cell-based assays
Watching the production of new proteins in live cells
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen
Scientists X-ray chocolate
AI-based analysis system for the diagnosis of breast cancer - For the first time, morphological, molecular and histological data are integrated in a single analysis
New organ-on-chip pilot seeks to reduce animal testing in consumer health industry - Cooperation between Bayer, the start-ups esqLABS and Dynamic42, and Placenta Lab of Jena University Hospital
A vast viral world in wastewater - How metagenomic sequencing helps to understand the spread of viruses